

December 15, 2025 - Press release

ORYZON announces the voting results of December 2025 Extraordinary General Shareholders' Meeting

- **37.8% of voting rights present or represented**
- **All resolutions were approved**

MADRID, SPAIN and CAMBRIDGE, USA, December 15, 2025 - Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share capital) were at the Meeting, either in person or represented by proxy.

The Company's shareholders approved all of the resolutions listed below, proposed by the Board of Directors at the Company's Extraordinary General Shareholders' Meeting, with favorable votes ranging from 93% to 98%.

- Technical amendment of Article 2 of the Company's Bylaws, relating to the corporate purpose, to adapt it to the New National Classification of Economic Activities (CNAE 2025).
- Amendment of Article 11 of the Company's Bylaws, relating to the remuneration of the Board of Directors.
- Approval of the new Remuneration Policy for directors, to be applied from the date of its approval and for the following three financial years, that is, during the 2026, 2027, and 2028 financial years.
- Approval of a 2026-2028 Long-Term Incentive Plan for executives and key personnel, including the Executive Chairman.
- Approval of a fixed long-term share-based remuneration to attract talent and reward the dedication of the independent directors of the Company's Board of Directors.
- Approval of a capital increase, through cash contributions and with the exclusion of preemptive subscription rights, for an effective amount of up to €125 million and delegation to the Board of Directors of the power to set the date, the issue price (or the procedure for determining it) and other conditions of the issue in accordance with the provisions of Article 505 of the Spanish Companies Act.
- Delegation of powers for the formalization, correction, registration, interpretation, development and execution of the resolutions adopted by the General Shareholders' Meeting.



The complete details of the resolutions that have been approved in their entirety and the results of the votes by separate items are available on the Company's website.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology/hematology. Oryzon's team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology/hematology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com

FORWARD-LOOKING STATEMENTS

This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates" and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration..

Spain

Patricia Cobo/Mario Cordera
Atrevia
+34 91 564 07 25
+34 673 33 97 65
pcobo@atrevia.com
mcordera@atrevia.com

Oryzon

Emili Torrell
Chief BD Officer
+34 93 515 1313
etorrell@oryzon.com

IR & Media, Europe & US

Sandya von der Weid
LifeSci Advisors, LLC
+41 78 680 05 38
svonderweid@lifesciadvisors.com